A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
- Status
- UNKNOWN
- Phase
- N/A
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
- Status
- UNKNOWN
- Phase
- PHASE2
Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone
- Status
- UNKNOWN
- Phase
- PHASE2
Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
- Status
- COMPLETED
- Phase
- PHASE3
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
- Status
- TERMINATED
- Phase
- N/A
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )
- Status
- UNKNOWN
- Phase
- PHASE2